Category: Pharmaceutical company
Quick infos Headquarters: Massachusetts, United States Trade prices Volume: Market Cap: 2.84B Prev closed: 81.6 Open: 82.12 High: 87.89 Low: 80.59 52 week low: 14.01 52 week high: 96.45 Dividends: No Dividends Next ER: August 4, 2021 Before Market Opens
About the Company Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPRâCas9 gene editing technology. The company went public on 2 Feb 2016.
Earnings History Date EPS / Forecast Revenue / Forecast November 10, 2021 August 4, 2021 -0.81 / -0.8235379K / 6.03MBeat! May 5, 2021 -0.86 / -0.74386.5M / 5.83MBeat! February 25, 2021 -1 / -0.7611.42M / 5.64MBeat! November 5, 2020 0.12 / -0.62662.84M / 6.36MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Sep 20, 2021 59.50 59.58 61.83
59.38
404.04K -5.85% Sep 17, 2021 63.20 61.00 63.54
59.23
2.17M 3.61% Sep 16, 2021 61.00 60.76 61.92
58.61
901.61K 1.16% Sep 15, 2021 60.30 60.68 61.27
58.90
1.32M -0.81% Sep 14, 2021 60.79 63.10 64.03
60.18
1.59M -3.45% Sep 13, 2021 62.96 66.43 67.36
62.60
1.56M -4.75% Sep 10, 2021 66.10 67.77 67.77
65.01
1.19M 2.56% Sep 9, 2021 64.45 64.26 67.61
64.08
848.44K 0.20% Sep 8, 2021 64.32 66.73 68.05
63.63
1.57M -3.61% Sep 7, 2021 66.73 68.06 72.50
66.69
1.85M -2.23% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company News
Editas Medicine Unveils Preclinical Data From New Gene Editing Technology finance.yahoo.com Sep 10, 2021 6:11 am
3 Red-Hot Healthcare Stocks to Buy in September fool.com Sep 9, 2021 12:37 pm
Initial Clinical Data from Editas Medicines BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September finance.yahoo.com Sep 7, 2021 4:00 pm
Is Editas Medicine (NASDAQ:EDIT) A Risky Investment? finance.yahoo.com Sep 1, 2021 8:15 am
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why finance.yahoo.com Aug 17, 2021 10:21 am
Editas Medicine Announces Pricing of Offering of Common Stock finance.yahoo.com Aug 9, 2021 10:30 pm
Why Editas Medicine Beat the Market on Monday fool.com Aug 9, 2021 6:05 pm Why Editas Medicine Stock Sank Today fool.com Aug 9, 2021 4:08 pm What Really Mattered With Editas Medicine's Q1 Update fool.com Aug 9, 2021 2:46 pm Why Editas Medicine Stock Is Getting Crushed Today fool.com Aug 9, 2021 2:39 pm
10 Best Up and Coming Stocks to Invest In finance.yahoo.com Aug 9, 2021 9:35 am
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com Aug 9, 2021 8:20 am Editas Medicine Falls as Goldman Sachs Initiates the Stock at Sell thestreet.com Aug 9, 2021 7:05 am
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates finance.yahoo.com Aug 9, 2021 8:15 am
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update finance.yahoo.com Aug 9, 2021 7:00 am
Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer finance.yahoo.com Aug 9, 2021 6:59 am
Intellia Soars On Positive Results In Gene-Editing Treatment finance.yahoo.com Aug 9, 2021 5:34 am Nasdaq Stays Flat as Workhorse Drives Higher, Editas Sinks fool.com Aug 5, 2021 3:31 pm
Goldman Sachs Just Put Editas Stock on Sale Buy the Dip finance.yahoo.com Aug 5, 2021 2:05 pm
Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y finance.yahoo.com Aug 5, 2021 12:43 pm This company doesn't provide a dividend.
Key Persons Talk about Editas below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written.
